Summary

The Europe calcineurin inhibitors market is expected to reach USD 4.47 billion by 2032 from USD 2.09 billion in 2024, growing with a CAGR of 10.0% in the forecast period of 2024 to 2032.

Market Segmentation:
Europe Calcineurin Inhibitors Market, By Drugs (Tacrolimus, Cyclosporine, Pimecrolimus, Voclosporin, and Others), Route of Administeration (Oral, Topical, Parenteral, and Others), Drug type (Branded and Generic), Application (Postoperative Immunosuppression, Atopic Dermatitis, Ulcerative Colitis, Psoriasis, Keratoconjunctivitis, and Others), End user (Hospitals, Specialty Clinics, Home Healthcare, Academic and Research Institutes, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (Germany, France, U.K., Italy, Spain, Switzerland, Netherlands, Russia, Turkey, Belgium, Austria, Ireland, Norway, Poland, and Rest Of Europe) - Industry Trends And Forecast To 2032

Overview of Europe Calcineurin Inhibitors Market Dynamics:

Driver
• Rising Prevalence Of Autoimmune Diseases
Restraint

• Limited Efficacy For Long-Term Use Of Calcineurin Inhibitors
Opportunity

• Growing Demand For Personalized Medicine

Market Players:

The key market players operating in the Europe calcineurin inhibitors market are listed below:

• Astellas Pharma US, Inc.
• Lupin
• Viatris Inc
• Glenmark Pharmaceuticals Inc.
• LEO Pharma Inc.
• Bausch Health Companies Inc.
• AbbVie Inc.
• SANDOZ
• Teva Pharmaceutical Industries Ltd.
• RPG Life Sciences Limited
• Dr. Reddy’s Laboratories Ltd
• Biocon
• Apotex Inc.
• Novaliq GmbH
• Sun Pharmaceutical Industries Ltd.
• ZAMBON COMPANY S.P.A.

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF THE EUROPE CALCINEURIN INHIBITORS MARKET 41
1.4 CURRENCY AND PRICING 43
1.5 LIMITATIONS 43
1.6 MARKETS COVERED 43
2 MARKET SEGMENTATION 47
2.1 MARKETS COVERED 47
2.2 GEOGRAPHICAL SCOPE 48
2.3 YEARS CONSIDERED FOR THE STUDY 49
2.4 DBMR TRIPOD DATA VALIDATION MODEL 50
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 53
2.6 MULTIVARIATE MODELLING 54
2.7 DBMR MARKET POSITION GRID 55
2.8 VENDOR SHARE ANALYSIS 56
2.9 SECONDARY SOURCES 57
2.10 ASSUMPTIONS 57
3 EXECUTIVE SUMMARY 58
4 PREMIUM INSIGHTS 63
4.1 PORTER’S FIVE FORCES 64
4.2 PESTEL ANALYSIS 65
5 APAC DEPRESSION SCREENING MARKET: REGULATIONS 66
5.1 REGULATORY AUTHORITIES IN NORTH AMERICA. 66
5.1.1 U.S. FOOD AND DRUG ADMINISTRATION (FDA) 66
5.1.2 HEALTH CANADA 67
5.1.3 FEDERAL COMMISSION FOR THE PROTECTION AGAINST SANITARY RISKS (COFEPRIS) - MEXICO 67
5.2 REGULATORY AUTHORITIES IN EUROPE. 68
5.2.1 GERMANY: 68
5.2.2 UNITED KINGDOM: 68
5.2.3 FRANCE: 68
5.2.4 ITALY: 68
5.2.5 SPAIN: 68
5.3 REGULATORY AUTHORITIES IN ASIA-PACIFIC. 69
5.3.1 JAPAN: 69
5.3.2 CHINA: 69
5.3.3 INDIA: 69
5.3.4 SOUTH KOREA: 69
5.3.5 AUSTRALIA: 70
5.4 REGULATORY AUTHORITIES IN MIDDLE EAST AND AFRICA. 70
5.4.1 SAUDI ARABIA: 70
5.4.2 UNITED ARAB EMIRATES (UAE): 70
5.4.3 EGYPT: 70
5.4.4 SOUTH AFRICA: 70
5.5 REGULATORY AUTHORITIES IN SOUTH AMERICA. 71
5.5.1 BRAZIL: 71
5.5.2 ARGENTINA: 71
5.5.3 COLOMBIA: 71
5.5.4 CHILE: 71
6 MARKET OVERVIEW 73
6.1 DRIVERS 75
6.1.1 RISING PREVALENCE OF AUTOIMMUNE DISEASES 75
6.1.2 INCREASING TRANSPLANTATION PROCEDURES 75
6.1.3 ADVANCEMENTS IN MEDICAL TECHNOLOGY 76
6.1.4 GOVERNMENT SUPPORT & FUNDING FOR TRANSPLANTS 77
6.2 RESTRAINTS 78
6.2.1 LIMITED EFFICACY FOR LONG-TERM USE OF CALCINEURIN INHIBITORS. 78
6.2.2 AVAILABILITY OF ALTERNATIVE IMMUNOSUPPRESSIVE THERAPIES. 78
6.3 OPPORTUNITIES 79
6.3.1 GROWING DEMAND FOR PERSONALIZED MEDICINE 79
6.3.2 GROWING GERIATRIC POPULATION 80
6.3.3 ADVANCEMENTS IN DRUG DELIVERY 80
6.4 CHALLENGES 81
6.4.1 COMPLEX DOSING AND MONITORING 81
6.4.2 HIGH COSTS 81
7 EUROPE CALCINEURIN INHIBITORS MARKET, BY DRUGS 82
7.1 OVERVIEW 83
7.2 TACROLIMUS 86
7.2.1 GENERIC 86
7.2.2 BRANDED 87
7.2.2.1 PROGRAF 87
7.2.2.2 ASTAGRAF XL 87
7.2.2.3 ENVARSUS XR 87
7.2.2.4 OTHER 87
7.2.2.4.1 CAPSULES 87
7.2.2.4.2 TABLETS 87
7.2.2.4.3 INJECTIONS 88
7.2.2.4.4 GRANULES FOR ORAL SUSPENSION 88
7.2.2.4.4.1 1 MG 88
7.2.2.4.4.2 0.5 MG 88
7.2.2.4.4.3 5 MG 88
7.2.2.4.4.4 OTHERS 88
7.2.2.4.4.5 ADULT 89
7.2.2.4.4.6 GERIATRIC 89
7.2.2.4.4.7 PEDIATRIC 89
7.3 CYCLOSPORINE 89
7.3.1 GENERIC 89
7.3.2 BRANDED 90
7.3.2.1 NEORAL 90
7.3.2.2 SANDIMMUNE 90
7.3.2.3 GENGRAF 90
7.3.2.4 OTHERS 90
7.3.2.4.1 CAPSULES 91
7.3.2.4.2 ORAL SOLUTION 91
7.3.2.4.3 INJECTION 91
7.3.2.4.4 OTHERS 91
7.3.2.4.4.1 100 MG 91
7.3.2.4.4.2 25 MG 91
7.3.2.4.4.3 50 MG 91
7.3.2.4.4.4 OTHERS 91
7.3.2.4.4.5 ADULT 92
7.3.2.4.4.6 PEDIATRIC 92
7.3.2.4.4.7 GERIATRIC 92
7.4 PIMECROLIMUS (TOPICAL CREAM) 92
7.4.1 GENERIC 92
7.4.2 BRANDED 92
7.4.2.1 ADULT 93
7.4.2.2 GERIATRIC 93
7.4.2.3 PEDIATRIC 93
7.5 VOCLOSPORIN (ORAL CAPSULE) 93
7.6 OTHERS 94
7.6.1 GENERIC 94
7.6.2 BRANDED 94
8 EUROPE CALCINEURIN INHIBITORS MARKET, BY DRUG TYPE 95
8.1 OVERVIEW 96
8.2 GENERIC 99
8.2.1 POSTOPERATIVE IMMUNOSUPPRESSION 99
8.2.2 ATOPIC DERMATITIS 99
8.2.3 ULCERATIVE COLITIS 99
8.2.4 PSORIASIS 100
8.2.5 KERATOCONJUNCTIVITIS 100
8.2.6 OTHERS 100
8.3 BRANDED 100
8.3.1 POSTOPERATIVE IMMUNOSUPPRESSION 101
8.3.2 ATOPIC DERMATITIS 101
8.3.3 ULCERATIVE COLITIS 101
8.3.4 PSORIASIS 101
8.3.5 KERATOCONJUNCTIVITIS 101
8.3.6 OTHERS 101
9 EUROPE CALCINEURIN INHIBITORS MARKET, BY APPLICATION 102
9.1 OVERVIEW 103
9.2 POSTOPERATIVE IMMUNOSUPPRESSION 106
9.3 ATOPIC DERMATITIS 106
9.4 ULCERATIVE COLITIS 107
9.5 PSORIASIS 107
9.6 KERATOCONJUNCTIVITIS 108
9.7 OTHERS 108
10 EUROPE CALCINEURIN INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION 109
10.1 OVERVIEW 110
10.2 ORAL 113
10.2.1 CAPSULE 113
10.2.2 TABLET 113
10.2.3 SOLUTION 113
10.3 TOPICAL 114
10.4 PARENTERAL 114
10.5 OTHERS 115
11 EUROPE CALCINEURIN INHIBITORS MARKET, BY END USER 116
11.1 OVERVIEW 117
11.2 HOSPITALS 120
11.3 SPECIALTY CLINICS 121
11.4 HOME HEALTHCARE 121
11.5 ACADEMIC AND RESEARCH INSTITUTES 122
11.6 OTHERS 122
12 EUROPE CALCINEURIN INHIBITORS MARKET, BY DISTRIBUTION CHANNEL 123
12.1 OVERVIEW 124
12.2 HOSPITAL PHARMACY 127
12.3 RETAIL PHARMACY 127
12.4 ONLINE PHARMACY 128
12.5 OTHERS 128
13 EUROPE CALCINEURIN INHIBITOR MARKET, BY REGION 129
13.1 EUROPE 131
14 EUROPE CALCINEURIN INHIBITORS MARKET, COMPANY LANDSCAPE 253
14.1 COMPANY SHARE ANALYSIS: EUROPE
15 SWOT ANALYSIS 254
16 COMPANY PROFILES 255
16.1 ASTELLAS PHARMA US, INC. 255
16.1.1 COMPANY SNAPSHOT 255
16.1.2 REVENUE ANALYSIS 256
16.1.3 COMPANY SHARE ANALYSIS 256
16.1.4 PRODUCT PORTFOLIO 257
16.1.5 RECENT DEVELOPMENT 257
16.2 CHUNGHWA CHEMICAL SYNTHESIS & BIOTECH CO., LTD 258
16.2.1 COMPANY SNAPSHOT 258
16.2.2 REVENUE ANALYSIS 258
16.2.3 COMPANY SHARE ANALYSIS 259
16.2.4 PRODUCT PORTFOLIO 259
16.2.5 RECENT DEVELOPMENT 259
16.3 LUPIN 260
16.3.1 COMPANY SNAPSHOT 260
16.3.2 REVENUE ANALYSIS 260
16.3.3 COMPANY SHARE ANALYSIS 261
16.3.4 PRODUCT PORTFOLIO 261
16.3.5 RECENT DEVELOPMENT 261
16.4 HUADONG MEDICINE CO.,LTD 262
16.4.1 COMPANY SNAPSHOT 262
16.4.2 REVENUE ANALYSIS 262
16.4.3 COMPANY SHARE ANALYSIS 263
16.4.4 PRODUCT PORTFOLIO 263
16.4.5 RECENT DEVELOPMENT 263
16.5 VIATRIS INC. 264
16.5.1 COMPANY SNAPSHOT 264
16.5.2 REVENUE ANALYSIS 264
16.5.3 COMPANY SHARE ANALYSIS 265
16.5.4 PRODUCT PORTFOLIO 265
16.5.5 RECENT DEVELOPMENT 265
16.6 APOTEX INC. 266
16.6.1 COMPANY SNAPSHOT 266
16.6.2 PRODUCT PORTFOLIO 266
16.6.3 RECENT DEVELOPMENT 266
16.7 ABBVIE INC 267
16.7.1 COMPANY SNAPSHOT 267
16.7.2 REVENUE ANALYSIS 267
16.7.3 PRODUCT PORTFOLIO 268
16.7.4 RECENT DEVELOPMENT 268
16.8 ACCORD HEALTHCARE US. 269
16.8.1 COMPANY SNAPSHOT 269
16.8.2 PRODUCT PORTFOLIO 269
16.8.3 RECENT DEVELOPMENT 269
16.9 ACTIZAPHARMA 270
16.9.1 COMPANY SNAPSHOT 270
16.9.2 PRODUCT PORTFOLIO 270
16.9.3 RECENT DEVELOPMENT 271
16.10 ADVACARE PHARMA 272
16.10.1 COMPANY SNAPSHOT 272
16.10.2 PRODUCT PORTFOLIO 272
16.10.3 RECENT DEVELOPMENT 272
16.11 BIOCON 273
16.11.1 COMPANY SNAPSHOT 273
16.11.2 REVENUE ANALYSIS 273
16.11.3 PRODUCT PORTFOLIO 274
16.11.4 RECENT DEVELOPMENT 274
16.12 BAUSCH HEALTH COMPANIES INC. 275
16.12.1 COMPANY SNAPSHOT 275
16.12.2 REVENUE ANALYSIS 275
16.12.3 PRODUCT PORTFOLIO 276
16.12.4 RECENT DEVELOPMENT 276
16.13 CONCORD BIOTECH 277
16.13.1 COMPANY SNAPSHOT 277
16.13.2 REVENUE ANALYSIS 277
16.13.3 PRODUCT PORTFOLIO 278
16.13.4 RECENT DEVELOPMENT 278
16.14 DR. REDDY’S LABORATORIES 279
16.14.1 COMPANY SNAPSHOT 279
16.14.2 REVENUE ANALYSIS 279
16.14.3 PRODUCT PORTFOLIO 280
16.14.4 RECENT DEVELOPMENT 280
16.15 GLENMARK PHARMACEUTICALS INC 281
16.15.1 COMPANY SNAPSHOT 281
16.15.2 REVENUE ANALYSIS 281
16.15.3 PRODUCT PORTFOLIO 282
16.15.4 RECENT DEVELOPMENT 282
16.16 LEO PHARMA INC. 283
16.16.1 COMPANY SNAPSHOT 283
16.16.2 PRODUCT PORTFOLIO 283
16.16.3 RECENT DEVELOPMENT 283
16.17 LIPELLA PHARMACEUTICALS, INC. 284
16.17.1 COMPANY SNAPSHOT 284
16.17.2 REVENUE ANALYSIS 284
16.17.3 PRODUCT PORTFOLIO 285
16.17.4 RECENT DEVELOPMENT 285
16.18 NOVARTIS AG 286
16.18.1 COMPANY SNAPSHOT 286
16.18.2 REVENUE ANALYSIS 286
16.18.3 PRODUCT PORTFOLIO 287
16.18.4 RECENT DEVELOPMENT 287
16.19 NOVALIQ GMBH 288
16.19.1 COMPANY SNAPSHOT 288
16.19.2 PRODUCT PORTFOLIO 288
16.19.3 RECENT DEVELOPMENT 288
16.20 PANACEA BIOTEC 289
16.20.1 COMPANY SNAPSHOT 289
16.20.2 REVENUE ANALYSIS 289
16.20.3 PRODUCT PORTFOLIO 290
16.20.4 RECENT DEVELOPMENT 292
16.21 PADAGIS 293
16.21.1 COMPANY SNAPSHOT 293
16.21.2 PRODUCT PORTFOLIO 293
16.21.3 RECENT DEVELOPMENT 293
16.22 RPG LIFE SCIENCES LIMITED 294
16.22.1 COMPANY SNAPSHOT 294
16.22.2 REVENUE ANALYSIS 294
16.22.3 PRODUCT PORTFOLIO 295
16.22.4 RECENT DEVELOPMENT 295
16.23 VELOXIS PHARMACEUTICALS, INC. 296
16.23.1 COMPANY SNAPSHOT 296
16.23.2 REVENUE ANALYSIS 296
16.23.3 PRODUCT PORTFOLIO 296
16.23.4 RECENT DEVELOPMENT 296
16.24 ZHAOKE OPHTHALMOLOGY LIMITED 297
16.24.1 COMPANY SNAPSHOT 297
16.24.2 REVENUE ANALYSIS 297
16.24.3 PRODUCT PORTFOLIO 298
16.24.4 RECENT DEVELOPMENT 298
16.25 ZAMBON COMPANY S.P.A. 299
16.25.1 COMPANY SNAPSHOT 299
16.25.2 PRODUCT PORTFOLIO 299
16.25.3 RECENT DEVELOPMENT 300
17 QUESTIONNAIRE 301
18 RELATED REPORTS 304